FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT	OF CHAN	GES IN	BENEFICIA	L OWNER	RSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response 0.5

S Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer 1. Name and Address of Reporting Person* Lantheus Holdings, Inc. [LNTH] (Check all applicable) Provost Jean-Claude Director 10% Owner Officer (give title Other (specify below) below) 3. Date of Earliest Transaction (Month/Day/Year) (Last) (First) (Middle) Chief Medical Officer 03/02/2023 C/O LANTHEUS HOLDINGS, INC. 201 BURLINGTON ROAD, SOUTH BLDG 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) (Street) Form filed by One Reporting Person **BEDFORD** 01730 MA Form filed by More than One Reporting (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities 6. Ownership Form: Direct (D) or Indirect 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 7. Nature of Date (Month/Day/Year) Execution Date, Indirect Beneficial Securities Beneficially Owned Following if any (Month/Day/Year) Code (Instr. 8) (I) (Instr. 4) Ownership Reported (Instr. 4) (A) or (D) Transaction(s) Code Price Amount (Instr. 3 and 4) Bv Theranostics Common Stock 03/02/2023 $A^{(1)}$ 16,359(2) \$0.00 20,823 A I Consulting SAS Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock Option (right to buy)	\$73.35	03/02/2023		A		9,535 ⁽²⁾		(3)	03/02/2033	Common Stock	9,535	\$0.00	9,535	I	By Theranostics Consulting SAS

Explanation of Responses:

- 1. Consists of 5,453 restricted stock units that vest in equal installments over a three-year period and 10,906 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award, however the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period.
- 2. The reporting person is the managing partner of the company that owns the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein
- 3. The option vests in three equal annual installments beginning on March 2, 2024.

Remarks:

03/06/2023 /s/ Eric Green, attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.